SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Tolera Therapeutics, Inc. Closes Series B-3 Financing, Raises $5.5 Million to Submit Phase 3 Special Protocol Assessment for Its Immune Targeting Biologic Drug in Kidney Transplantation